Genentech/Roche cancels CREED-1 and d CREED 2 Phase III trials of crenezumab for Alzheimer's Disease
Genentech, a member of the Roche Group, announced the decision to discontinue CREAD 1 and CREAD 2 (BN29552 and BN29553) Phase III studies of the investigational anti-beta-amyloid molecule crenezumab in people with early (prodromal to mild) sporadic Alzheimer�s disease (AD).
The decision was based on the results of a pre-planned interim analysis assessing the safety and efficacy of crenezumab conducted by the Independent Data Monitoring Committee, which indicated that crenezumab was unlike . No safety signals for crenezumab were observed in this analysis, and the overall safety profile was similar to that seen in previous trials. Data from the CREAD 1 and 2 studies will be shared with the scientific community at an upcoming medical congress. Findings from the trials will inform future research programs, approaches and clinical trial designs.
Related news and insights
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma